Celecoxib, a highly selective COX-2 inhibitor, has been shown to suppress neuronal hyperexcitability and reduce seizure frequency in pilocarpine- and kainate-induced epilepsy models, suggesting its potential therapeutic utility in epilepsy management (Lim et al., 2019) In addition, MCC950, an NLRP3 inflammasome inhibitor, has demonstrated significant neuroprotective effects in animal studies by reducing neuronal damage after status epilepticus (SE) and alleviating depressive-like behaviors, representing a novel avenue for precision anti-inflammatory therapy (Hong et al., 2024). This evidence concerns the gene PTGS2 and epilepsy.